India has firmly established itself as the world's major producer of generic drugs. It is currently ranked third in ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of ...

The European Medicines Agency (EMA) could table proposals next year to relax requirements around the need for comparative ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster ...

The U.S. FDA approved 15 drugs in October, marking a decline from 24 in September and 22 in August. Despite the drop, the 2024 monthly average stands at about 19 approvals, exceeding last year’s ...

The major pharmaceutical companies of the country reported a 10 per cent year-on-year (YoY) growth in the second quarter of ...

South Korean biosimilar giant Celltrion announced Friday that its biosimilars, Stoboclo and Osenvelt, have been approved by the Ministry of Food and Drug Safety. The two biosimilars, referencing Amgen ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The Ministry of Food and Drug Safety (MFDS) approved South Korea’s first denosumab (Prolia/Xgeva) biosimilars, developed by Celltrion Inc. under the brand names of Stoboclo/Osenvelt (CT-P41) for ...